Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

590

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2030

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

SHR-8068

SHR-8068: injection, 50 mg/10 mL, intravenous infusion

DRUG

Adebrelimab

Adebrelimab: injection, 600 mg/12 mL, intravenous infusion

DRUG

Bevacizumab

Bevacizumab: injection, 100 mg/4 mL, intravenous infusion

DRUG

Sintilimab

Sintilimab: injection, 100 mg/10 mL, intravenous infusion

Trial Locations (1)

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY